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Effects of the copper intrauterine device
versus injectable progestin contraception on
pregnancy rates and method discontinuation
among women attending termination of
pregnancy services in South Africa: a
pragmatic randomized controlled trial
G. Justus Hofmeyr1, Mandisa Singata-Madliki1, Theresa A. Lawrie1,5*, Eduardo Bergel4 and Marleen Temmerman2,3

Abstract
Background: The copper intrauterine device (IUD) is under-utilised in South Africa, where injectable progestin
contraception (IPC) dominates contraception usage. There is a lack of robust comparative data on these
contraceptive options to inform policy, programs, clinical counseling, and women’s choices.
Methods: Within the context of a South African program to increase women’s access to the IUD, we conducted a
pragmatic, open-label, parallel-arm, randomised controlled trial of the IUD versus IPC at two South African hospitals.
The target sample size was 7,000 women and the randomisation ratio was 1:1. The random sequence was
computer-generated and group allocation was concealed in sealed, opaque, consecutively-numbered envelopes.
Counselled, consenting women attending termination of pregnancy services were randomly assigned to IUD or IPC
immediately post-termination. Condoms were promoted for the prevention of sexually-transmitted infections. The
primary outcome was pregnancy; secondary outcomes were discontinuation, side-effects, and HIV acquisition and
disease progression. Pregnancy and discontinuation outcomes are reported here.
Results: The trial closed early with 2,493 participants randomised (IUD = 1,247, IPC = 1,246), due to international
concerns regarding a possible association between IPC and HIV acquisition. Median follow-up was 20 months; 982
and 1000 participants were followed up in the IUD and IPC groups, respectively. Baseline group characteristics were
comparable. Pregnancy occurred significantly less frequently among women allocated to the IUD than IPC: 56/971
(5.8 %) versus 83/992 (8.4 %), respectively; risk ratio (RR) 0.69, 95 % confidence interval (CI) 0.50 to 0.96; P = 0.025.
There were more protocol violations in the IUD group; however, discontinuation rates were similar between IUD
and IPC groups (141/855 [16.5 %] and 143/974 [14.7 %], respectively). Women in the IUD group were more likely to
discontinue contraceptive use due to abdominal pain or backache and non-specific symptoms, and those in the
IPC group due to oligo- or amenorhoea and lack of sexual activity.
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Conclusions: The IUD was significantly more effective in preventing pregnancy than IPC. Efforts to expand
contraception options and improve access to the IUD in settings where it is under-utilised are worthwhile. This trial
shows that randomising long-acting, reversible contraceptives is feasible.
Trial registration: Pan African Clinical Trials Registry number PACTR201409000880157 (04-09-2014).
Keywords: DMPA, IUD, Random

Background
More than 4,000 terminations of pregnancy are performed
each year in the East London/Mdantsanes area of South
Africa and, in a survey of postnatal women attending local
hospitals and clinics, two thirds of births were unintended
[1]. Like most of South Africa, women utilising services at
Frere and Cecelia Makiwane Hospitals and clinics have a
limited choice of contraceptives and injectable progestin
contraception (IPC), including depot medroxyprogesterone acetate (DMPA) and norethisterone enantate (NET),
account for most contraception use. A common reason
for discontinuation of contraception by women attending
these services is dissatisfaction with the contraceptive
method. The World Health Organization (WHO) continues to highlight the need for a wider variety of highly
effective contraceptive methods to be available to women
living in low and middle-income countries (LMICs) [2].
The copper intrauterine device (IUD) is a wellestablished, highly effective method of contraception;
however, availability issues, staff capacity, provider attitude, and perception of side effects have held back its
use in many LMICs, including South Africa [3–5]. In
2005, we initiated a program at Frere and Cecelia
Makiwane Hospitals and clinics to expand contraceptive
options to include the copper IUD (SMB® Model TCu
380A), which was previously unavailable in our services.
However, we found comparative data on the relative
contraceptive effectiveness of the IUD and IPC to be
insufficient for adequate counselling of prospective
users: Limited evidence from a 2010 Cochrane review
suggested that the IUD was more effective in preventing
unintended pregnancy than hormonal contraception
(including IPC), but had not been further elucidated [6];
and observational data were subject to confounding as
contraceptive choice often varies according to factors related to the likelihood of pregnancy. To enhance the
knowledge base for our counselling and promotion of
wider contraception options, we designed a pragmatic
trial within our routine contraceptive services to compare effectiveness, method discontinuation, and reasons
for discontinuation, of the newly introduced method
(IUD) with that of the most widely-used method (IPC).
As secondary outcomes, we also assessed side effects,

HIV acquisition and HIV/AIDS disease progression,
which we intend to report separately.

Methods
Study design and participants

The trial was a pragmatic, open-label, parallel arm randomised controlled trial conducted at two Eastern Cape
hospitals, Frere Hospital (FH) and Cecelia Makiwane
Hospital (CMH), in South Africa. Recruitment began on
6 July 2009 and ended on 8 November 2012. Women attending termination of pregnancy services at the study
sites, who met the inclusion criteria and requested longterm contraception with no personal preference for a
particular method, were counselled in their home language and offered participation in the trial. Women were
eligible if they intended to continue contraception for at
least one year, were ≥ 16 years old, had no evidence of
active pelvic infection on history and clinical examination, had no contraindications to IPC or IUD use, were
prepared to use either method of contraception, understood the patient information form, and were willing to
sign informed consent. All women were offered counselling and voluntary HIV testing at baseline and at followup, according to national health policy, using rapid tests
or laboratory-based ELISA tests. Those with positive results were offered a CD4 count and treatment according
to national health guidelines.
Ethics, consent, and permissions

Ethical approval for the trial was obtained from the
University of the Witwatersrand Committee for Research
on Human Subjects, South Africa, on the 25 April 2008,
clearance certificate M080466. Signed informed consent to
participate in the study was obtained from all participants.
Randomisation

An allocation list was prepared using a computergenerated random sequence in balanced blocks of variable
size and with a randomisation ratio of 1:1. Allocation slips
were inserted into consecutively-numbered, opaque envelopes and sealed by a member of staff not involved in the
trial. The randomisation list was sealed in a signed envelope by the same staff member for safekeeping. The
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randomisation envelopes were distributed to the study
sites in batches of 100. Women who agreed to participate
were entered onto a trial register and then enrolled by
opening the next numbered, sealed envelope. The point of
trial entry was at the opening of the envelope.
Interventions

Women were fully counselled about their allocated
contraception method prior to its administration. In the
IUD group, the IUD was inserted after termination of
pregnancy, which was usually performed by manual vacuum aspiration by the hospital staff following routine
procedures. Antibiotic prophylaxis was not used. The
women were offered two options regarding the string
placement after full counselling about the relative benefits of each: strings protruding from the cervix by about
2 cm, or strings inserted completely within the uterine
cavity or removed. The reason for offering these options
is that many women in our services prefer their contraception to be confidential. In the IPC arm, women were
counselled regarding the need for repeat injections at
regular intervals. The first injection was administered by
hospital staff according to routine practice and, in most
instances, DMPA was used. However, as this was a pragmatic trial within the routine contraception services, allowance was made for the use of NET at the discretion
of the provider. Women received no additional reminders to support continuation with the allocated
contraception method, and no payments or other incentives were offered, other than payment of transport costs
for the final visit at 12 months post-enrolment.
Outcomes

The primary outcome was pregnancy. Secondary outcomes were method discontinuation, side effects, HIV
acquisition, and HIV/AIDS disease progression. Pregnancy and discontinuation outcomes are reported in
this paper.
Data collection

Professional nurses who worked as research assistants
completed a Good Clinical Practice certification course
before trial commencement. Participant baseline details
were entered onto a paper case report form (CRF), including demographic data, medical history, and baseline
data relevant to the follow-up questionnaire (including
sexual activity and potential side effects). Follow-up
questionnaires were administered by the research assistants to participants by telephone at three, six, nine and
12 months after randomisation. The CRF and questionnaire were piloted before the main trial. The actual
contraceptive method received after randomisation was
collected retrospectively from family planning registers
at the two hospitals. Participants were requested to
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attend an interview at the hospital 12 months after enrolment, failing which the interview was conducted by
telephone. Initial and final contraceptive methods used
were confirmed with the participant at the last interview.
Other questions at this interview included whether the
participant had been pregnant since joining the study,
the outcome of the pregnancy, and what contraceptive
methods had been used since joining the study, as well
as reasons for discontinuation. Attempts to contact
women who did not return for follow-up were continued
until study closure in June 2014. Research assistants advised participants to attend the relevant health facility
for any health concerns.
Sample size and analysis

The sample size was calculated based on the primary outcome. To detect a reduction in unplanned pregnancy from
2.5 % to 1.5 %, we calculated that we needed 6,546 participants (alpha = 0.05, beta = 0.20; Epi Info™ statistical software version 7). To allow for loss to follow-up, we
planned to recruit a total sample size of 7,000 women.
Intention-to-treat analysis was performed for the primary outcome (pregnancy) using Epi Info™ statistical software. Discontinuation rate was defined as the proportion
of women who did not continue use of the allocated
method to follow-up, out of the women initiating the allocated method and this analysis was, thus, per protocol.
Baseline characteristics were compared between enrolled groups, as well as those with follow up of 12 months
or more. For categorical variables, the rates of outcome
events were compared as risk ratios (RR) with 95 % confidence intervals (CI). P-values were calculated using the
Chi-squared test with Mantel-Haenszel correction or, for
small numbers, the Fisher’s exact test. P values of less than
0.05 were regarded as statistically significant.
Trial registration

Registration of the protocol with the South African
National Clinical Trials Register was undertaken on
15 September 2008 (Verification Code: 0–953). It
was subsequently found not to have been logged by
the system, and was re-registered with the Pan
African Clinical Trials Registry on 4th September 2014
(PACTR201409000880157). (http://apps.who.int/trialsearch/
Trial2.aspx?TrialID=PACTR201409000880157).

Results
The trial closed early due to international concerns regarding a possible association between DMPA and HIV
acquisition, following publication of an observational
study reporting increased HIV acquisition among women
who chose DMPA [7], and the subsequent plan by international stakeholders to conduct a large, multicentre trial
that could address the DMPA/HIV question [8].
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At closure, 2,493 of the target sample had accrued
(36 %), with 1,247 and 1,246 women randomised to the
IUD and IPC groups, respectively. An additional 19 randomisation envelopes could not be linked to participants
(see CONSORT Fig. 1). Baseline data for the IUD and
IPC groups were well matched (Table 1). Data on the
primary outcome were available for 1,963 participants
(78.7 %). The median time to final interview was
20 months (interquartile range 15 to 28). In the IUD
group, 56 out of 971 women (5.8 %) became pregnant
during follow-up compared with 83 out of 992 women
(8.4 %) in the IPC group (risk ratio (RR) 0.69, 95 % confidence interval (CI) 0.50 to 0.96; P = 0.025). There were
no statistically significant differences between groups for
the type of pregnancy outcome (Table 2).
Data on discontinuation were available for 982 women
(78.7 %) in the IUD group and 1000 women (80.3 %) in
the IPC group. In the IUD group, 855 (87.1 %) of the
982 women received an IUD as allocated; the other 127
women (12.9 %) received a non-allocated method
(protocol violations), which was an IPC in most (125)
cases. In the IPC group, 974 out of 1000 women
(97.4 %) received an IPC as allocated, with 85.5 % receiving DMPA; the remainder received NET. Twenty-three
out of the 26 women in the IPC group receiving a nonallocated method (protocol violations) received an IUD,
and follow-up data did not distinguish between DMPA
and NET. At the final follow-up interview, 729 women
(74.2 %) out of 982 women in the IUD group were using
an IUD, compared with 831 (83.1 %) out of 1000 women
in the IPC group (intention-to-treat). Loss to follow-up
was relatively high and, in the worse case scenario, if all
those lost to follow-up were not using the allocated
method, the percentage of women using the allocated

Participants randomised (n=2493)

Allocated to IPC

(n=1246)

Lost to follow-up (n=246)

Allocated to IUD (n=1247)

Lost to follow-up (n=265)

Analysed at median of 20

Analysed at median of 20

months (n=1000)

months (n=982)

Received initially:

Received initially:

IPC (n=974)

IUD (n=855)

IUD (n=23)

IPC (n=125)

OC (n=3)

OC (n=2)

Fig. 1 CONSORT diagram showing the flow of participants
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method at follow-up in the IUD and IPC groups was
58.5 % and 66.7 %, respectively. However, among women
who initiated their allocated treatment as per protocol,
discontinuation at a median follow-up of 20 months was
not statistically significantly difference between the IUD
and the IPC groups (141/855 women [16.5 %] versus
143/974 women [14.7 %], respectively; RR 1.12, 95 % CI
0.91 to 1.39; P = 0.29) (Table 3).
Women in the IUD group were more likely than those
in the IPC group to discontinue contraceptive use due to
abdominal pain or backache (P = 0.00005) and nonspecific symptoms (P = 0.004), and those in the IPC group
were more likely to discontinue due to oligo-or amenorhoea (P = 0.004) and lack of sexual activity (P = 0.0002)
(Table 4). Expulsion of the IUD was given as the reason
for discontinuation in 26/135 (19.3 %) women who discontinued IUD use, giving an expulsion rate of 3 %. Two
women in the IUD group and four women in the IPC
group were reported to have died during the follow-up
period. Information on these women is shown in Table 5.

Discussion
As mentioned above, during the conduct of our trial an
observational study published findings of increased HIV
acquisition among women who chose DMPA contraception, which gained wide media attention [7]. Trial investigators attended international stakeholder consultations,
where there were calls for a large, multicentre trial to
conclusively answer the questions on the effects of hormonal contraception on HIV acquisition and disease
progression [2]. In such a trial, any evidence relating to
DMPA should be robust and distinct from other longacting, progestin contraceptives. As the current pragmatic trial was unable to unequivocally answer the
DMPA/HIV question due to the allowance of DMPA or
NET in the IPC group, we stopped recruitment in
November 2012. We followed up the reduced sample as
planned with the aim of using these data to inform the
design of the requisite, more robust trial [8].
Nevertheless, the sample size was adequate to assess
the primary outcome due to the occurrence of higher
than expected pregnancy rates in this trial. In contraceptive guidelines, contraceptive failure with typical use is
considered to be about six pregnancies per 100 womenyears with IPC use, and one per 100 women-years with
IUD use [9]. The estimate for IPC failure is supported
by our findings, and those of a recent observational
study of contraceptive use in South Africa, which reported pregnancy rates with IPC of 4.4 per 100 womenyears [3]. However, pregnancy rates in women allocated
to IUD use in our study, although significantly lower
with the IUD than IPC, were higher than expected. This
was probably partly due to over-estimation on intentionto-treat analysis, as 13 % of women allocated to the IUD
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Table 1 Baseline data expressed as numbers (%) or mean values (standard deviation (SD))
IUD group

IPC group

n (%) or mean [SD]

N

n (%) or mean [SD]

N

26.7 [6.3]

1234

26.4 [6.1]

1239

Weight in kgs

71.7 [17.9]

1214

70.2 [16.4]

1220

Previous miscarriage

107 (8.7)

1235

100 (8.1)

1232

Previous caesarean section

163 (13.3)

1230

146 (11.8)

1236

Previous pelvic sepsis

241 19.6)

1230

237 (19.2)

1232

Hypertension

14 (1.1)

1236

11 (0.9)

1242

Diabetes mellitus

5 (0.4)

1236

6 (0.5)

1241

HIV positive

236 (21.2)

1110

240 (21.6)

1118

Age in years

Previous contraception use
-IPC

801 (71.1)

1126

824 (72.5)

1136

-oral contraceptive pill

90 (7.7)

1176

64 (5.4)

1184

-IUD

2 (0.2)

1177

1 (0.1)

1188

IUD intrauterine device, IPC injectable progestin contraception

group received IPC. Thus, our findings provide robust
evidence that allocation to the IUD is more effective
than allocation to IPC in preventing unintended pregnancies in South Africa. This has important implications
for contraceptive policy in South Africa, where injectable
progestin contraception accounts for the vast majority of
contraception in the public sector and efforts to improve
the method mix have had limited success.
A large study of more than 200,000 women from 14
developing countries reported a median probability of
IUD discontinuation of 13.2 % [10]. Higher rates of IUD
and IPC discontinuation (and unintended pregnancy)
have been observed among women with a history of termination of pregnancy [11–14]. In two post-termination
cohorts of women who chose IPC, discontinuation rates
as high as 64 per 100 woman-years, and 84 % were reported [13, 14]. As all the participants in our trial were
recruited post-termination of pregnancy, this factor may
have contributed to contraceptive failure and discontinuation in our trial.

Due to the pragmatic nature of this trial, loss to
follow-up was relatively high, at around 20 % in both
intervention groups. This limitation could have lead to
an under-estimation of method discontinuation due to
differential loss of women who discontinued their allocated method. For this reason we reported the proportion of women using each method out of those with
known follow up data, as well as for of the intervention
groups as a whole. Baseline characteristics were comparable, therefore, loss to follow-up did not appear to have
been differential between random allocation groups. Another limitation of the trial was the high number of
protocol violations in the IUD group; 12.7 % of women
with follow-up data in the IUD group received the IPC
after randomisation instead of the IUD. The reasons for
protocol violations were not recorded, but could have
been due to women declining the IUD after randomisation in favour of the more familiar method (IPC), or difficulties with IUD insertion, or provider barriers. Of the
participants with data on previous contraceptive use,

Table 2 Pregnancy rates and outcomes
IUD group (N = 971)

IPC group (N = 992)

RR

95 % CI

P-value (M-H)

8.4

0.69

0.50 to 0.96

0.025

41

4.1

0.72

0.45 to 1.15

0.17

3

0.3

0.2

2

0.2

0

1

0.1

16

1.6

29

2.9

0.56

0.31 to 1.03

0.059

6

0.6

7

0.7

n

%

n

%

56

5.8

83

Birth

29

3

Miscarriage

3

0.3

Termination

2

Ectopic

0

Ongoing
Unknown

Pregnancy (total)
Pregnancy outcome:

IUD intrauterine device, IPC injectable progestin contraception, RR risk ratio, CI confidence interval, M-H mantel-haenszel chi square 2-tail
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Table 3 Allocated and actual contraception method and discontinuation
Allocated method
IUD

IPC

Actual method/s used

N

% final method known

% total

N

% final method known

% total

Initial method used: IUD

855

87.1 %

68.6 %

23

2.3 %

1.8 %

714

72.7 %

0.1 %

21

2.1 %

1.7 %

Initial method/final method:
IUD/IUD
IUD/IPC

32

3.3 %

2.6 %

0

0.0 %

0.0 %

IUD/OC

4

0.4 %

0.3 %

0

0.0 %

0.0 %

IUD/Sterilisation

1

0.1 %

0.1 %

0

0.0 %

0.0 %

IUD/none

104

10.6 %

8.3 %

2

0.2 %

Initial method used: IPC

125

12.7 %

10.0 %

974

97.4 %

78.2 %

IPC/IPC

105

10.7 %

8.4 %

831

83.1 %

66.7 %

IPC/IUD

15

1.5 %

1.2 %

11

1.1 %

0.9 %

IPC/OC

0

0.0 %

0.0 %

11

1.1 %

0.9 %

IPC/sterilisation

0

0.0 %

0.0 %

3

0.3 %

0.2 %

IPC/none

5

0.5 %

0.4 %

118

11.8 %

9.5 %

Initial method used: Other

2

0.2 %

0.2 %

3

0.3 %

0.2 %

OC/OC

2

0.2 %

0.2 %

3

0.3 %

0.2 %

Final method known

982

78.7 %

1000

80.3 %

Final method unknown

265

21.3 %

246

19.7 %

Total randomised

1247

Initial method/final method:

1246

IUD intrauterine device, IPC injectable progestin contraception

Table 4 Discontinuation and reasons
Reason for discontinuation (total)

IUD group

IPC group
135

RR

95 % CI

P-value (M-H)

0.8

0.46 to 1.37

0.41

147

Want baby/married

19

14.1

26

17.7

Fell pregnant

3

2.2

1

0.7

Abdominal pain/backache

21

15.6

3

2

7.62

2.33 to 25

0.00005

Heavy menstruation

9

6.7

13

8.8

0.75

0.33 to 1.71

0.5

Scanty/no menstruation

0

0

9

6.1

0

NE

0.004 (FE)

Not sexually active

11

8.1

36

24.5

0.33

0.18 to 0.63

0.0002

6.5

1.49 to 29

0.004

0.53

0.35 to 0.82

0.003

Weight gain

0

0

3

2

Weight loss

1

0.7

0

0

Partner request

1

0.7

0

0

Discomfort during intercourse

1

0.7

0

0

Infection

2

1.5

0

0

Itchy vulvae/discharge

2

1.5

0

0

Headaches

0

0

1

0.7

Non-specific symptoms

12

8.9

2

1.4

Using condoms

1

0.7

4

2.7

Suspected cancer

1

0.7

0

0

No reason given

25

18.5

49

33.3

IUD came out

26

19.3

0

0

IUD intrauterine device, IPC injectable progestin contraception, RR risk ratio, CI confidence interval, M-H mantel-haenszel chi square 2-tail
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Table 5 Women reported to have died
Age (y) Baseline HIV status Weight (Kg) Group allocation Option received Date enrolled Approximate date of death Reported cause of death
31

Unknown

81

IUD

IUD

02-Sep-09

2012

Motor vehicle accident

24

Unknown

65

IUD

IUD

24-Feb-10

15-May-10

Motor vehicle accident

18

Negative

67

IP

DMPA

13-Jul-10

Dec-11

Eclampsia

32

Positive

?

IP

DMPA

08-Nov-10

18-Dec-11

Knife wound/s

26

Positive

49

IP

DMPA

10-Nov-11

10-Feb-12

HIV-related infection

20

Negative

60

IP

NET

07-Aug-12

May-13

Asthmatic attack

1625 had previously used IPC versus only three previously using the IUD (Table 3). Whilst protocol violations
may have underestimated differences between contraceptive methods on pregnancy rates, in intention-totreat analysis they are unlikely to have over-estimated
effect differences.
While individual choice is a cornerstone of contraceptive services, this trial demonstrates that after counseling
on different contraceptive options many women did not
have a specific preference for a contraceptive method and
were willing to agree to randomisation without any financial remuneration or other benefits. Although initial compliance in the IUD group was sub-optimal (87 %), the
acceptability of randomisation is supported by the fact
that discontinuation of allocated methods were comparable with observational studies in which women had
chosen their contraceptive method [10–14]. No trialrelated steps were taken to support adherence to the allocated contraception method, and no payments or other
incentives were offered, other than payment of transport
costs for the final visit at 12 or more months postrandomisation. In addition, the provision and follow up of
the allocated contraceptive method took place within the
routine health service. The advantage of this was that relative discontinuation rates and contraceptive effectiveness
were more likely to reflect the ‘typical-use’ effect of these
methods in routine practice (though absolute rates might
differ from women choosing a specific method). The disadvantage was that follow-up was less efficient and protocol violations were higher than might have been achieved
with a more intensive research intervention.

Conclusions
The IUD was more effective than IPC in a posttermination of pregnancy setting in South Africa. Disontinuation rates with the IUD were comparable to the more
familiar and widely accepted IPC, suggesting that efforts
to expand contraception method choice and overcome
user and provider barriers to IUDs are worthwhile. Study
limitations such as protocol violations may have led to an
under-estimation of differences in the primary outcome,
but over-estimation is unlikely. This research supports the
feasibility of conducting a large, multi-centre randomised
trial to address the DMPA/HIV question.
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